|
1
|
Liu Y, Shete S, Hosking F, Robertson L,
Houlston R and Bondy M: Genetic advances in glioma: Susceptibility
genes and networks. Curr Opin Genet Dev. 20:239–244. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: European Organisation for Research and Treatment of
Cancer Brain Tumor and Radiotherapy Groups; National Cancer
Institute of Canada Clinical Trials Group: Radiotherapy plus
concomitant and adjuvant temozolomide for glioblastoma. N Engl J
Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Okada H, Kohanbash G, Zhu X, Kastenhuber
ER, Hoji A, Ueda R and Fujita M: Immunotherapeutic approaches for
glioma. Crit Rev Immunol. 29:1–42. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Flies DB, Sandler BJ, Sznol M and Chen L:
Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J
Biol Med. 84:409–421. 2011.PubMed/NCBI
|
|
5
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Koguchi K, Anderson DE, Yang L, O'Connor
KC, Kuchroo VK and Hafler DA: Dysregulated T cell expression of
TIM3 in multiple sclerosis. J Exp Med. 203:1413–1418. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhu C, Anderson AC, Schubart A, Xiong H,
Imitola J, Khoury SJ, Zheng XX, Strom TB and Kuchroo VK: The Tim-3
ligand galectin-9 negatively regulates T helper type 1 immunity.
Nat Immunol. 6:1245–1252. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ju Y, Hou N, Meng J, Wang X, Zhang X, Zhao
D, Liu Y, Zhu F, Zhang L, Sun W, et al: T cell immunoglobulin- and
mucin-domain-containing molecule-3 (Tim-3) mediates natural killer
cell suppression in chronic hepatitis B. J Hepatol. 52:322–329.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lemke D, Pfenning PN, Sahm F, Klein AC,
Kempf T, Warnken U, Schnölzer M, Tudoran R, Weller M, Platten M and
Wick W: Costimulatory protein 4IgB7H3 drives the malignant
phenotype of glioblastoma by mediating immune escape and
invasiveness. Clin Cancer Res. 18:105–117. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wainwright DA, Chang AL, Dey M,
Balyasnikova IV, Kim CK, Tobias A, Cheng Y, Kim JW, Qiao J, Zhang
L, et al: Durable therapeutic efficacy utilizing combinatorial
blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.
Clin Cancer Res. 20:5290–5301. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
De Groot CJ, Montagne L, Janssen I, Ravid
R, Van Der Valk P and Veerhuis R: Isolation and characterization of
adult microglial cells and oligodendrocytes derived from postmortem
human brain tissue. Brain Res Brain Res Protoc. 5:85–94. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Olah M, Raj D, Brouwer N, De Haas AH,
Eggen BJ, Den Dunnen WF, Biber KP and Boddeke HW: An optimized
protocol for the acute isolation of human microglia from autopsy
brain samples. Glia. 60:96–111. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Berns K, Horlings HM, Hennessy BT,
Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM,
Stemke-Hale K, Hauptmann M, et al: A functional genetic approach
identifies the PI3K pathway as a major determinant of trastuzumab
resistance in breast cancer. Cancer Cell. 12:395–402. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mack PC, Redman MW, Chansky K, Williamson
SK, Farneth NC, Lara PN Jr, Franklin WA, Le QT, Crowley JJ and
Gandara DR: SWOG: Lower osteopontin plasma levels are associated
with superior outcomes in advanced non-small-cell lung cancer
patients receiving platinum-based chemotherapy: SWOG Study S0003. J
Clin Oncol. 26:4771–4776. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang L, He S, Tu Y, Ji P, Zong J, Zhang J,
Feng F, Zhao J, Gao G and Zhang Y: Downregulation of chromatin
remodeling factor CHD5 is associated with a poor prognosis in human
glioma. J Clin Neurosci. 20:958–963. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ji Y, Wei Y, Wang J, Ao Q, Gong K and Zuo
H: Decreased expression of microRNA-107 predicts poorer prognosis
in glioma. Tumour Biol. 36:4461–4466. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Monney L, Sabatos CA, Gaglia JL, Ryu A,
Waldner H, Chernova T, Manning S, Greenfield EA, Coyle AJ, Sobel
RA, et al: Th1-specific cell surface protein Tim-3 regulates
macrophage activation and severity of an autoimmune disease.
Nature. 415:536–541. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Asakura H, Kashio Y, Nakamura K, Seki M,
Dai S, Shirato Y, Abedin MJ, Yoshida N, Nishi N, Imaizumi T, et al:
Selective eosinophil adhesion to fibroblast via IFN-gamma-induced
galectin-9. J Immunol. 169:5912–5918. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Park WS, Jung WK, Park SK, Heo KW, Kang
MS, Choi YH, Kim GY, Park SG, Seo SK, Yea SS, et al: Expression of
galectin-9 by IFN-γ stimulated human nasal polyp fibroblasts
through MAPK, PI3K, and JAK/STAT signaling pathways. Biochem
Biophys Res Commun. 411:259–264. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ungerer C, Quade-Lyssy P, Radeke HH,
Henschler R, Königs C, Köhl U, Seifried E and Schüttrumpf J:
Galectin-9 is a suppressor of T and B cells and predicts the immune
modulatory potential of mesenchymal stromal cell preparations. Stem
Cells Dev. 23:755–766. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Anderson AC, Anderson DE, Bregoli L,
Hastings WD, Kassam N, Lei C, Chandwaskar R, Karman J, Su EW,
Hirashima M, et al: Promotion of tissue inflammation by the immune
receptor Tim-3 expressed on innate immune cells. Science.
318:1141–1143. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rolle CE, Sengupta S and Lesniak MS:
Mechanisms of immune evasion by gliomas. Adv Exp Med Biol.
746:53–76. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Anderson AC: Tim-3, a negative regulator
of anti-tumor immunity. Curr Opin Immunol. 24:213–216. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fourcade J, Sun Z, Benallaoua M, Guillaume
P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V and Zarour HM:
Upregulation of Tim-3 and PD-1 expression is associated with tumor
antigen-specific CD8+ T cell dysfunction in melanoma patients. J
Exp Med. 207:2175–2186. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sakuishi K, Apetoh L, Sullivan JM, Blazar
BR, Kuchroo VK and Anderson AC: Targeting Tim-3 and PD-1 pathways
to reverse T cell exhaustion and restore anti-tumor immunity. J Exp
Med. 207:2187–2194. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Baitsch L, Baumgaertner P, Devêvre E,
Raghav SK, Legat A, Barba L, Wieckowski S, Bouzourene H, Deplancke
B, Romero P, et al: Exhaustion of tumor-specific CD8+ T cells in
metastases from melanoma patients. J Clin Invest. 121:2350–2360.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Calinescu AA, Kamran N, Baker G, Mineharu
Y, Lowenstein PR and Castro MG: Overview of current
immunotherapeutic strategies for glioma. Immunotherapy.
7:1073–1104. 2015. View Article : Google Scholar : PubMed/NCBI
|
